Agios Pharmaceuticals, Inc.: 5%+ holders

As of November 6, 2026, 7 holders' latest Schedule 13D or 13G filings report owning 5% or more of Agios Pharmaceuticals, Inc. The largest reported stake is Farallon Capital Management, L.L.C.'s, at 9.9%. 14 filings are on record since July 7, 2025 (Schedule 13G/A, August 3, 2026).

Who owns Agios Pharmaceuticals, Inc.?

Bellevue Group AG also filed stake reports on 6 other companies ↓

Sell to companies like Agios Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filing 2026-08-03 · Reporting person: Farallon Capital Management, L.L.C. · Sole voting: 0 · Shared voting: 5,917,400 · Sole dispositive: 0 · Shared dispositive: 5,917,400 · SCHEDULE 13G/A, 2026-08-03
• Filed 2026-07-02 · Holder: D. E. Shaw & Co., L.P. · Percent: 5.1% · SCHEDULE 13G
• Filed 2026-05-15 · Holder: Armistice Capital, LLC · Percent: 4.57% · SCHEDULE 13G/A
• Filed 2026-05-06 · Holder: Lynx1 Capital Management LP · Percent: 5.1% · SCHEDULE 13G
• Filed 2026-04-29 · Holder: Vanguard Capital Management · Percent: 5.27% · SCHEDULE 13G

Agios Pharmaceuticals, Inc. has 14 Schedule 13D or 13G filings on record since 2025-07-07. 7 holders' latest filing reports 5% or more of common stock, par value $0.001 per share (the "shares"). Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind Agios Pharmaceuticals, Inc. and the warning signs.

See Agios Pharmaceuticals, Inc.'s free Snapshot Watch Agios Pharmaceuticals, Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on Agios Pharmaceuticals, Inc. and the records around it.

Agios Pharmaceuticals, Inc. elsewhere on the record

• Who owns it

Companies that share a holder

• Bellevue Group AG also filed stake reports on 6 other companies: Yarrow Bioscience, Inc. (Oct 2026), Jade Biosciences, Inc. (Aug 2026), Celldex Therapeutics, Inc. (May 2026)
• Lynx1 Capital Management LP also filed stake reports on 11 other companies: C4 Therapeutics, Inc. (Aug 2026), GH Research PLC (Aug 2026), iBio, Inc. (Aug 2026)
• Farallon Capital Management, L.L.C. also filed stake reports on 18 other companies: EXELIXIS, INC. (Nov 2026), ENANTA PHARMACEUTICALS INC (Aug 2026), InflaRx N.V. (Aug 2026)

Want the whole picture on Agios Pharmaceuticals, Inc.?

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on Agios Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Agios Pharmaceuticals, Inc. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   14 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies Agios Pharmaceuticals, Inc. by CUSIP 00847X104 and gives its principal executive office as 88 Sidney Street, Cambridge, MA 02139 (SCHEDULE 13G/A, 2026-08-03).

Timeline

Swipe the table sideways to see every column.

Questions about who owns Agios Pharmaceuticals, Inc.

Who owns Agios Pharmaceuticals, Inc.?

On this page, 7 holders' latest ownership filings report 5% or more of Agios Pharmaceuticals, Inc.: Farallon Capital Management, L.L.C. (9.9%, Schedule 13G/A, filed 2026-08-03), Dapice Joshua J. (8.8%, Schedule 13G/A, filed 2026-02-09), BlackRock, Inc. (7.8%, Schedule 13G/A, filed 2025-07-17), State Street Corporation (5.3%, Schedule 13G, filed 2026-02-09) and Vanguard Capital Management (5.27%, Schedule 13G, filed 2026-04-29); 2 more are listed above.

Who are the largest shareholders of Agios Pharmaceuticals, Inc.?

By the share each holder's latest filing reports, the largest holders of Agios Pharmaceuticals, Inc. on this page are Farallon Capital Management, L.L.C. (9.9%), Dapice Joshua J. (8.8%) and BlackRock, Inc. (7.8%).

When did Farallon Capital Management, L.L.C. buy into Agios Pharmaceuticals, Inc.?

The filings give report dates, not purchase dates. The earliest filing from Farallon Capital Management, L.L.C. on this page is the Schedule 13G/A, filed 2026-08-03, reporting 9.9%. That earliest filing is itself an amendment, which updates an earlier report.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 14 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Tools for this story

Each opens in a new tab, filled in for Agios Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.

• Get an alert when Agios Pharmaceuticals, Inc. is mentioned again
• Find former Agios Pharmaceuticals, Inc. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes